Therapy development
Develops enzyme replacement and gene therapies for LSDs.
M6P Therpeutics
Compiled from public sources
Unclaimed business
Unclaimed
- Claim to manage details & reply to reviews
- Pro profile & priority placement
- Reedleys Recognition & certificate
About M6P Therpeutics
The company develops therapies for lysosomal storage disorders, including enzyme replacement and gene therapy products. Its S1S3 co-expression platform is used to develop lysosomal enzymes phosphorylated with mannose 6-phosphate, supporting treatment development for these rare diseases. Work spans drug discovery and non-clinical, clinical, and commercial development. M6P Therapeutics focuses on translating its platform technology into next-generation treatments for people affected by lysosomal storage disorders. The company is based in St. Louis, Missouri. Its specialties include enzyme replacement therapy and gene therapy development for lysosomal storage disorders.
Disclosure: Profile information has been compiled from publicly available sources and has not yet been verified by the business.
Category illustration. Illustrative image for this category. Not provided by the business.
Highlights
S1S3 platform
Uses co-expression technology to develop phosphorylated lysosomal enzy
Rare disease focus
Works on treatments for lysosomal storage disorders.
M6P Therpeutics Reviews
No reviews yet — be the first to review M6P Therpeutics.
Write a review
Sign in to write a review
or get a one-click link by email
No password needed. We only use your email to confirm the review is genuine.
No reviews match this filter.